1. A Phase IIb, randomized, placebo‐controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Issue 8 (4th March 2013) Authors: Ferrannini, E.; Seman, L.; Seewaldt‐Becker, E.; Hantel, S.; Pinnetti, S.; Woerle, H. J. Journal: Diabetes, obesity & metabolism Issue: Volume 15:Issue 8(2013:Aug.) Page Start: 721 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta‐analysis of data from randomized placebo‐controlled trials. Issue 10 (24th August 2016) Authors: Salsali, A.; Kim, G.; Woerle, H. J.; Broedl, U. C.; Hantel, S. Journal: Diabetes, obesity & metabolism Issue: Volume 18:Issue 10(2016) Page Start: 1034 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Issue 12 (9th October 2015) Authors: Chilton, R.; Tikkanen, I.; Cannon, C. P.; Crowe, S.; Woerle, H. J.; Broedl, U. C.; Johansen, O. E. Journal: Diabetes, obesity & metabolism Issue: Volume 17:Issue 12(2015:Dec.) Page Start: 1180 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Efficacy and safety of empagliflozin twice daily versus once daily in patients with type 2 diabetes inadequately controlled on metformin: a 16‐week, randomized, placebo‐controlled trial. Issue 7 (13th May 2015) Authors: Ross, S.; Thamer, C.; Cescutti, J.; Meinicke, T.; Woerle, H. J.; Broedl, U. C. Journal: Diabetes, obesity & metabolism Issue: Volume 17:Issue 7(2015:Jul.) Page Start: 699 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add‐on to metformin in type 2 diabetes with mild hyperglycaemia. Issue 12 (22nd August 2013) Authors: Rosenstock, J.; Seman, L. J.; Jelaska, A.; Hantel, S.; Pinnetti, S.; Hach, T.; Woerle, H. J. Journal: Diabetes, obesity & metabolism Issue: Volume 15:Issue 12(2013:Dec.) Page Start: 1154 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Empagliflozin as add‐on to metformin in people with Type 2 diabetes. Issue 12 (14th July 2015) Authors: Merker, L.; Häring, H‐U.; Christiansen, A. V.; Roux, F.; Salsali, A.; Kim, G.; Meinicke, T.; Woerle, H. J.; Broedl, U. C. Journal: Diabetic medicine Issue: Volume 32:Issue 12(2015:Dec.) Page Start: 1555 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4‐week, randomized, placebo‐controlled trial (EASE‐1). Issue 10 (24th June 2015) Authors: Pieber, T. R.; Famulla, S.; Eilbracht, J.; Cescutti, J.; Soleymanlou, N.; Johansen, O. E.; Woerle, H. J.; Broedl, U. C.; Kaspers, S. Journal: Diabetes, obesity & metabolism Issue: Volume 17:Issue 10(2015:Oct.) Page Start: 928 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Empagliflozin improves glycaemic and weight control as add‐on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24‐week, randomized, placebo‐controlled trial. Issue 2 (22nd August 2013) Authors: Kovacs, C. S.; Seshiah, V.; Swallow, R.; Jones, R.; Rattunde, H.; Woerle, H. J.; Broedl, U. C. Journal: Diabetes, obesity & metabolism Issue: Volume 16:Issue 2(2014:Feb.) Page Start: 147 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial. Issue 10 (14th July 2015) Authors: Rosenstock, J.; Jelaska, A.; Zeller, C.; Kim, G.; Broedl, U. C.; Woerle, H. J.; on behalf of the EMPA‐REG BASALTM trial investigators Journal: Diabetes, obesity & metabolism Issue: Volume 17:Issue 10(2015:Oct.) Page Start: 936 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Lack of drug–drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and warfarin in healthy volunteers. Issue 4 (22nd November 2012) Authors: Macha, S.; Rose, P.; Mattheus, M.; Pinnetti, S.; Woerle, H. J. Journal: Diabetes, obesity & metabolism Issue: Volume 15:Issue 4(2013:Apr.) Page Start: 316 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗